Dr. Rochlin is the VP of Operations & Innovation at IN8bio, a clinical-stage biotechnology company developing novel gamma-delta T cell therapies for Cancer. She is responsible for company development, pipeline buildout, strategy development and implementation. She has over 15 years of experience in early-stage biotechnology and company development, including scientific research, IP strategy, operations and strategic & business development. She joins from Curadigm, a Cambridge-based biotechnology where she held various senior roles, most recently as Chief Business Officer where she led the company spin-out from Nanobiotix and developed collaborations around a novel platform to increase therapeutic bioavailability. Crain?s New York Business recognized Kate as one of the top women in tech in 2019. Prior to this she served as the Director of Scientific Affairs at Filament BioSolutions, developing therapeutics in oncology supportive care, specifically for oral mucositis. She is a scientific and business advisor to Immunovent, a New York-based biotechnology company she Co-Founded. Dr. Rochlin also serves as an executive board member to The Solution Lab, a New York-based non-profit providing Ph.D. and MBA students with real-world consulting experiences. Dr. Rochlin earned a Ph.D. in Molecular Biology and Genetics from Weill Cornell Medical College, conducting research at Sloan Kettering Institute, and a BA in Biology from the University of Pennsylvania.